---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-008257"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T22:02:02.463704+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical Q2 fiscal 2025: operating loss narrows to $1.5M, clinical trial advances

## Summary
- Cash balance $5.8M at Sept 30, 2025; operating expenses down 48% YoY to $1.5M.
- Operating loss narrowed to $1.5M from $2.8M in the prior-year quarter.
- Nasdaq compliance resolved; AEMD remains listed on the Capital Market.
- Recruitment began for Cohort 2 of Australian Hemopurifier oncology trial with pembrolizumab/nivolumab.
- Long COVID research with UCSF continues; manuscript in preparation for peer-reviewed journal.

## SEC filing metadata
- accession: 0001683168-25-008257
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316825008257/0001683168-25-008257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316825008257/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-008257
- JSON: https://secwatch.observer/filing/0001683168-25-008257.json
- Plain text: https://secwatch.observer/filing/0001683168-25-008257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.